#1 Clinical Trials Search in Europe

Nnc0194-0499

NNC0194-0499 is an investigational drug being studied for the treatment of various liver conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcohol-related liver disease. This article summarizes the key findings from several clinical trials exploring the safety, effectiveness, and pharmacokinetics of NNC0194-0499 in different patient populations.

Table of Contents

What is NNC0194-0499?

NNC0194-0499 is a new investigational medicine being developed by Novo Nordisk for the treatment of liver diseases[1]. It is currently undergoing clinical trials to evaluate its safety and effectiveness. NNC0194-0499 is not yet approved by health authorities for use outside of research studies[1].

What conditions does NNC0194-0499 treat?

NNC0194-0499 is being investigated for the treatment of several liver conditions:

  • Non-alcoholic fatty liver disease (NAFLD): A condition where excess fat builds up in the liver of people who drink little or no alcohol[1].
  • Non-alcoholic steatohepatitis (NASH): A more severe form of NAFLD that includes liver inflammation and damage[2].
  • Alcohol-related liver disease: Liver damage caused by excessive alcohol consumption[3].

These conditions can lead to serious liver problems if left untreated, including scarring of the liver (cirrhosis) and liver failure.

How is NNC0194-0499 administered?

NNC0194-0499 is given as an injection under the skin (subcutaneous injection). In clinical trials, it has been administered in various ways:

  • As a single dose[1]
  • Once weekly injections for several weeks[4]
  • In combination with other medications[5]

The exact dosing and administration schedule may vary depending on the specific study and condition being treated.

Clinical Trials of NNC0194-0499

Several clinical trials are being conducted to evaluate NNC0194-0499:

  • Studies in healthy volunteers to understand how the drug behaves in the body[1][2]
  • Trials in people with various degrees of liver disease[6]
  • Research on its effects in people with obesity[4]
  • Investigations of its use in combination with other medications[5]

These trials aim to determine the safety, effectiveness, and optimal dosing of NNC0194-0499 for different patient groups.

Potential Side Effects

As NNC0194-0499 is still in the research phase, all of its potential side effects are not yet known. Clinical trials are carefully monitoring for any adverse events (unwanted effects) that may occur. Common measures being tracked include:

  • Changes in heart rate and blood pressure[4]
  • Effects on liver and kidney function[6]
  • Changes in blood tests (e.g., cholesterol levels)[5]
  • Injection site reactions[4]

It’s important to note that not all participants will experience side effects, and the safety profile of the drug is still being established through ongoing research.

Combination Therapy with Semaglutide

Some studies are investigating the use of NNC0194-0499 in combination with another drug called semaglutide[5]. Semaglutide is an approved medication used to treat type 2 diabetes and obesity. Researchers believe that combining these two drugs may provide better results in treating NASH than either drug alone[5].

The combination therapy is being studied to see if it can:

  • Reduce liver damage
  • Improve liver function
  • Help with weight loss
  • Manage blood sugar levels in people with diabetes

Ongoing Research

NNC0194-0499 is still in the early stages of development. Ongoing and future studies will help determine:

  • The most effective dose of the medication
  • Long-term safety and effectiveness
  • Which patients are most likely to benefit from the treatment
  • How it compares to or combines with other liver disease treatments

It’s important to note that as an investigational drug, NNC0194-0499 is not currently available for general use. Patients interested in this treatment should speak with their healthcare providers about the possibility of participating in clinical trials.

Aspect Details
Drug Name NNC0194-0499
Conditions Studied Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Alcohol-related liver disease
Administration Method Subcutaneous injection
Dose Ranges Various, including 3.0 mg, 9.0 mg, 12 mg, 27 mg, 30 mg, 60 mg, 96 mg, 120 mg
Study Populations Healthy volunteers, Overweight/obese individuals, Patients with liver diseases, Various ethnic groups (Chinese, Japanese, Non-Asian)
Primary Outcomes Safety, Tolerability, Pharmacokinetics
Secondary Outcomes Changes in liver enzymes, lipid profiles, body weight, alcohol use markers
Combination Therapies NNC0194-0499 with semaglutide, NNC0194-0499 with cagrilintide
Study Durations Ranging from single-dose studies to 24-week treatments

FAQ

  • What is NNC0194-0499? NNC0194-0499 is an investigational drug being developed for the treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It is administered as an injection under the skin.
  • What conditions is NNC0194-0499 being studied for? NNC0194-0499 is being studied for various liver conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and alcohol-related liver disease.
  • How is NNC0194-0499 administered? NNC0194-0499 is typically administered as a subcutaneous injection, meaning it is injected under the skin, usually in the stomach area or thigh.
  • What are the main goals of the clinical trials involving NNC0194-0499? The main goals of the clinical trials are to assess the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of NNC0194-0499. Some trials also aim to evaluate its effectiveness in treating liver diseases.
  • Are there any combination therapies being studied with NNC0194-0499? Yes, some clinical trials are investigating the use of NNC0194-0499 in combination with other drugs such as semaglutide and cagrilintide for the treatment of liver diseases and related conditions.

Ongoing Clinical Trials on Nnc0194-0499

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Non-alcoholic fatty liver disease (NAFLD): A condition where excess fat builds up in the liver of people who drink little or no alcohol.
  • Non-alcoholic steatohepatitis (NASH): A more severe form of NAFLD, characterized by liver inflammation and damage in addition to fat accumulation.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect.
  • Dose escalation: A process in clinical trials where the dose of a drug is gradually increased to determine the optimal dose and safety profile.
  • Steady state: The point at which the amount of drug in the body remains constant, with the rate of drug administration equaling the rate of drug elimination.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used to assess the drug's concentration in the body.
  • Cmax: The maximum concentration of a drug in the blood after administration.
  • Half-life: The time it takes for the concentration of a drug in the body to be reduced by half.

References

  1. https://clinicaltrials.gov/study/NCT05742919
  2. https://clinicaltrials.gov/study/NCT04722653
  3. https://clinicaltrials.gov/study/NCT06409130
  4. https://clinicaltrials.gov/study/NCT03479892
  5. https://clinicaltrials.gov/study/NCT05016882
  6. https://clinicaltrials.gov/study/NCT05727644